IP Library › Granted Patent US 10,751,396
Granted Patent B2
US 10,751,396 · App. 15/547,137 · Granted Aug 25, 2020

Early hyperlipidemia promotes endothelial activation via a caspase-1-sirtuin 1 pathway

Inventor: Xiaofeng Yang (Huntingdon Valley, PA)
Assignee: Temple University—Of The Commonwealth System of Higher Education
A61K38/50A61K31/7088A61K39/395C07K14/4703C07K14/4747C12N9/80C12N15/00C12Y305/01
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,751,396
App. No.
15/547,137
Granted
Aug 25, 2020
Kind
B2
Abstract

The present invention provides compositions and methods for treating or preventing a disease or disorder associated with endothelial activation, inflammation or atherogenesis, including but not limited to cardiovascular diseases and inflammatory disorders.

Claims (8)

1. An inhibitor of caspase-1 activity comprising a non-cleavable Sirt1 peptide inhibitor, wherein the non-cleavable Sirt1 peptide inhibitor is at least one of:

a) Mouse nc-Sirt1:

(SEQ ID NO: 1)

RQIKIWFQNRRMKWKKGYRDNLLLTAGLLTNGFHSC;

or

b) Human nc-Sirt1:

(SEQ ID NO: 2)

RQIKIWFQNRRMKWKKGYRDNLLFGAEIITNGFHSC.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2020
From: YANG, XIAOFENG
To: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Reel/Frame 052619/0910 →
Continuity (2)
Provisional Application 62109918 · Jan 30, 2015
Related Publication 20180015152A1 · Jan 18, 2018